Details:

Alternative Title:
MMWR Morb Mortal Wkly Rep
Personal Author:
Surie, Diya ; Bonnell, Levi ; Adams, Katherine ; Gaglani, Manjusha ; Ginde, Adit A. ; ... More +
Surie, Diya ; Bonnell, Levi ; Adams, Katherine ; Gaglani, Manjusha ; Ginde, Adit A. ; Douin, David J. ; Talbot, H. Keipp ; Casey, Jonathan D. ; Mohr, Nicholas M. ; Zepeski, Anne ; McNeal, Tresa ; Ghamande, Shekhar ; Gibbs, Kevin W. ; Files, D. Clark ; Hager, David N. ; Shehu, Arber ; Frosch, Anne P. ; Erickson, Heidi L. ; Gong, Michelle N. ; Mohamed, Amira ; Johnson, Nicholas J. ; Srinivasan, Vasisht ; Steingrub, Jay S. ; Peltan, Ithan D. ; Brown, Samuel M. ; Martin, Emily T. ; Khan, Akram ; Bender, William S. ; Duggal, Abhijit ; Wilson, Jennifer G. ; Qadir, Nida ; Chang, Steven Y. ; Mallow, Christopher ; Rivas, Carolina ; Kwon, Jennie H. ; Exline, Matthew C. ; Lauring, Adam S. ; Shapiro, Nathan I. ; Halasa, Natasha ; Chappell, James D. ; Grijalva, Carlos G. ; Rice, Todd W. ; Stubblefield, William B. ; Baughman, Adrienne ; Womack, Kelsey N. ; Hart, Kimberly W. ; Swan, Sydney A. ; Zhu, Yuwei ; DeCuir, Jennifer ; Tenforde, Mark W. ; Patel, Manish M. ; McMorrow, Meredith L. ; Self, Wesley H. ; Calhoun, Nicole ; Herrick, Judy ; Hoffman, Eric ; McKillop, Amanda ; Murthy, Kempapura ; Smith, Michael ; Zayed, Martha ; De Souza, Lesley ; Kozikowski, Lori-Ann ; Ouellette, Scott ; Ashok, Kiran ; Gole, Susan ; King, Alexander ; Mehkri, Omar ; Poynter, Bryan ; ten Lohuis, Caitlin ; Stanley, Nicholas ; Caspers, Sean ; Hendrickson, Audrey ; Kaus, Olivia ; Taghizadeh, Leyla ; Tordsen, Walker ; Aston, Valerie ; Bowers, Robert ; Jorgensen, Jeffrey ; King, Jennifer ; Ali, Harith ; Rothman, Richard E. ; Chen, Jen-Ting ; Nair, Rahul ; Allada, Gopal ; Briceno, Genesis ; Giovanni, Shewit ; Hubel, Kinsley A. ; Martinez, Jesus ; Oh, Minn ; Pak, Jonathan ; Pena, Jose ; Gordon, Alexandra Jun ; Levitt, Joe ; Perez, Cynthia ; Roque, Jonasel ; Visweswaran, Anita ; Karow, Sarah ; Khan, Maryiam ; Klingler, Austin ; Pannu, Sarah ; Smith, David ; Schwartz, Elizabeth ; Snyder, Connor ; So, Madison ; So, Preston ; Swoope, Gabrielle ; Weigand, Michael ; Carricato, Michael ; Chambers, Ian ; Driver, Conner ; Goff, Jennifer ; Huynh, David ; Jensen, Kelly ; Chandrasekaran, Sukantha ; Frankel, Trevor ; Garner, Omai ; Fairfield, Catherine ; Landers, Shannon ; Nassar, Paul ; Williams, Cameron ; Gershengorn, Hayley ; Bielak, Ramsay ; Blair, Christopher ; Fitzsimmons, William J. ; Fong, Rebecca ; Gilbert, Julie ; McSpadden, EJ ; Thomas, Lara ; Truscon, Rachel ; Valvano, Weronika Damek ; Anderson, Layla A. ; Crider, Christine D. ; Paulson, Thomas C. ; Steinbock, Kyle A. ; Blair, Marica ; Ezzell, Lauren J. ; Hargrave, Samarian J. ; Kampe, Christy ; Johnson, Jakea ; Luther, Jennifer L. ; McHenry, Rendie E. ; Peterson, Bryan P. M. ; Pulido, Claudia Guevara ; Short, Laura L. ; Whitsett, Margaret E. ; Hicks, Madeline ; Landreth, Leigha ; LaRose, Mary ; Parks, Lisa ; Babcock, Hilary ; Hink, Tiffany ; Jolani, Kevin ; McDonald, David ; O’Neal, Caroline ; Parikh, Bijal ; Parrish, Katie ; Samuels, Carleigh Less -
Corporate Authors:
IVY Network
Description:
The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late December 2021 (1). BA.1 has since been replaced by emerging lineages BA.2 (including BA.2.12.1) in March 2022, followed by BA.4 and BA.5, which have accounted for a majority of SARS-CoV-2 infections since late June 2022 (1). Data on the effectiveness of monovalent mRNA COVID-19 vaccines against BA.4/BA.5-associated hospitalizations are limited, and their interpretation is complicated by waning of vaccine-induced immunity (2-5). Further, infections with earlier Omicron lineages, including BA.1 and BA.2, reduce vaccine effectiveness (VE) estimates because certain persons in the referent unvaccinated group have protection from infection-induced immunity. The IVY Network| assessed effectiveness of 2, 3, and 4 doses of monovalent mRNA vaccines compared with no vaccination against COVID-19-associated hospitalization among immunocompetent adults aged ≥18 years during December 26, 2021-August 31, 2022. During the BA.1/BA.2 period, VE 14-150 days after a second dose was 63% and decreased to 34% after 150 days. Similarly, VE 7-120 days after a third dose was 79% and decreased to 41% after 120 days. VE 7-120 days after a fourth dose was 61%. During the BA.4/BA.5 period, similar trends were observed, although CIs for VE estimates between categories of time since the last dose overlapped. VE 14-150 days and >150 days after a second dose was 83% and 37%, respectively. VE 7-120 days and >120 days after a third dose was 60%and 29%, respectively. VE 7-120 days after the fourth dose was 61%. Protection against COVID-19-associated hospitalization waned even after a third dose. The newly authorized bivalent COVID-19 vaccines include mRNA from the ancestral SARS-CoV-2 strain and from shared mRNA components between BA.4 and BA.5 lineages and are expected to be more immunogenic against BA.4/BA.5 than monovalent mRNA COVID-19 vaccines (6-8). All eligible adults aged ≥18 years| should receive a booster dose, which currently consists of a bivalent mRNA vaccine, to maximize protection against BA.4/BA.5 and prevent COVID-19-associated hospitalization.
Subjects:
[+]
Adolescent Adult COVID-19 COVID-19 Vaccines Full Report Hospitalization Humans RNA, Messenger SARS-CoV-2 United States Vaccines, Combined
Source:
MMWR Morb Mortal Wkly Rep. 71(42):1327-1334
Pubmed ID:
36264830
Pubmed Central ID:
PMC9590291
Document Type:
Journal Article
Funding:
K23 GM129661/GM/NIGMS NIH HHSUnited States/ ; T32 GM135169/GM/NIGMS NIH HHSUnited States/
K23 GM129661/GM/NIGMS NIH HHSUnited States/ ; T32 GM135169/GM/NIGMS NIH HHSUnited States/ Less -
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:669b7ae7a2572b952585e0e3f35a9c36430b8c8c10ebadc6d78d4da4ded44477
Download URL:
https://stacks.cdc.gov/view/cdc/122704/cdc_122704_DS1.pdf
File Type:

Supporting Files

• 	mm7142a3-F.gif	gif
  	mm7142a3-F.jpg	jpeg
  	mm7142a3.nxml	xml

More +